Relationship of serum cystatin C with C-reactive protein and apolipoprotein A1 in patients on hemodialysis

Renal Failure

Volumn 30, Issue 7, 2008, Pages 711-715

  Samouilidou, Elisabeth C ^a   Grapsa, Eirini ^a  

^a ALEXANDRA HOSPITAL   (Greece)

Author keywords

Apolipoprotein A1; C reactive protein; Cystatin C; Hemodialysis

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; CYSTATIN C; HIGH DENSITY LIPOPROTEIN; LIPID; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; ARTIFICIAL KIDNEY; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY DISEASE; LIPID ANALYSIS; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

ANALYSIS OF VARIANCE; APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; CYSTATINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MULTIVARIATE ANALYSIS; PROBABILITY; REFERENCE VALUES; RENAL DIALYSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 49649108836     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220802212973     Document Type: Article

References (38)

1. Bökenkamp A, Herget-Rosenthal S, Bökenkamp S. Cystain C, kidney function and cardiovascular disease. Pediatr Nephrol. 2006;21:1223-1230.
2. Trof R, di Maggio F, Leemreis J, Groeneveld J. Biomarkers of acute injury and renal failure. Shock. 2006;26:245-253.
3. Heilman R, Mazur M. Cystain C is a more sensitive indicator of diminished glomerular filtration rate. Liver Tranplant. 2005;11:264-266.
4. Newman DJ. Cystatin C. Ann Clin Biochem. 1990;268:287-294.
5. Abrahamson M, Olafson J, Palsodottir A, et al. Structure and expression of human cystatin C gene. Biochem J. 1990;268:287-294.
6. Tenstad O, Roald AB, Grubb A, Aukland K. Renal handling of radio labeled human cystatin C in the rat. Scand J Clin Lab Invest. 1996:56:409-414.
7. Price CP, Finney H. Developments in the assessment of glomerular filtration rate. Clin Chim Acta. 2000;297:55-66.
8. Grubb A, Simonsen O, Sturfelt G, Truedsson L, Thyssel H. Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand. 1985;218:499-503.
9. Bostom AG, Dworkin LD. Cystain C measurement: Improved detection of mild decrements in glomerular filtration rate versus creatine-based estimates. Am J Kidney Dis. 2000;36:2005-2007.
10. Van der Noortgate NJ, Janssens WH, Delanghe JR, Afschrift MB, Lameire NH. Serum cystatin C concentration compared with other markers of glomerular filtration rate in the old age. J Am Geriatr Soc. 2002;50:1278-1282.
11. Herget-Rosenthal S, Marggraf G, Hüsing J, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004;66:1115-1122.
12. Lamb E, Riordan S, Delaney M. Kidney function in older people: Pathology assessment and management. Clin Chim Acta. 2003;34:25-40.
13. Herget-Rosenthal S, Trabold S, Pietruck F, et al. Cystatin C efficacy as screening test for reduced glomerular filtration rate. Am J Nephrol. 2000;20:97-102.
14. Luc G, Bard JM, Lesueur C, Arveiler D, Evans A, Amouyel P, et al. Plasma cystatin C and development of coronary heart disease: The PRIME study. Atherosclerosis. 2006;185:375-380.
15. Arimoto T, Takeishi Y, Niizeki T, Takabatake N, Okouyama H, et al. Cystatin C, a novel measure of renal function is an independent predictor of cardiac events in patients with heart failure. J Card Failure. 2005;11:595-601.
16. Koenig W, Twardella D, Brenner H, Rothernbacher D. Plasma concentration of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: More than simply a marker of glomerular filtration rate. Clin Chemistry. 2005;51:321-327.
17. Campo A, Lanfranco G, Gramaglia L, Goia F, Giusto V. Could plasma cystatin C be useful as marker of hemodialysis low molecular weight removal? Nephron Clin Pract. 2004;98:C79-C82.
18. Locsey L, Szegredi J, Dan A, Gorogh S, Toths E. Homocysteine and cystatin C level changes in hemodialyzed patients and connection with cerebro- and cardiovascular complications. Acta Physiol Hung. 2001;88:293-299.
19. Blirup-Jensen S. Protein standardization III: Method of optimization. Basic principles for quantitative determination of human serum proteins on automated instruments based on turbidimetry or nephelometry. Clin Chem Lab Med. 2001;39:1098-1109.
20. Sjöstrom P, Tidman M, Jones I. Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerural filtration rate from the serum concentration of cystatin C in humans. Scand J Clin Lab Inv. 2005;65:111-124.
21. Krieter D, Falkenhain S, Chalabi L, Collins G, Lemke H, Canaud B. Clinical cross-over comparison of mid-dilution hemodiafiltration using novel dialyzer concept and post-dilution hemodiafiltration. Kidney Int. 2005;67:349-356.
22. Testa A, Gentilhomme H, Le Carrer D, et al. In vivo removal of high and low molecular weight compounds in hemodiafiltration with on-line generation of ultrafiltrate. Nephron Clin Pract. 2006;104:c55-c60.
23. Tsirpanlis G. Is inflammation the link between atherosclerosis and vascular calcification in chronic kidney disease? Blood Purif. 2007;25:179-182.
24. Guerin A, Pannier B, London G. Atherosclerosis versus arterial stiffness in advanced renal failure. Adv Cardiol. 2007;44:187-198.
25. Leung-Tack J, Tavera C, Martinez J, Colte A. Neutrophil chemeotactic activity is modulated by human cystatin C, an inhibitor of cystein proteases. Inflammation. 1990;14:247-257.
26. Descamps-Latscha B, Goldford B, Nguyen AT. Establishing the relationship between complement activation and stimulation of phagocyte oxidative metabolism in hemodialysed patients. Nephron. 1991;59:279-285.
27. Ateş K, Yilmaz O, Kutlay S, et al. Serum C-reactive protein level is associated with renal function and it affects echocardigraphic cardiovascular disease in pre-dialysis patients. Nephron Clin Pract. 2005;101:C190-C197.
28. Finney H, Newman DJ, Price CP. Adult reference ranges of serum cystatin C, creatinine and predicted creatinine clearance. Ann Clin Biochem. 2000;37:49-59.
29. Vinge E, Lindergard B, Nilsson-Ehle P, Grubb A. Relationships among serum cystatin C, lean tissue mass and glomerular filtration rate in healthy adults. Scand J Clin Lab Inv. 1999;59:587-592.
30. Jonston N, Jernberg A, Lindball J, Stridberg M, Larsson A, Venge P, Wallentin L. Biochemical indicators of cardiac and renal function in healthy elderly population. Clin Biochem. 2004;37:210-216.
31. Knight E, Verhave J, Spiegelman D, Hillege H, et al. Factors influencing cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:1416-1421.
32. Gökkusu C, Ozden TA, Güll H, et al. Relationship between plasma cystatin A and creatinine in chronic renal diseases and Tx-transplant patients. Clin Biochem. 2004;37: 94-97.
33. Codognotto M, Piccoli A, Zaninotto M, et al. Cystatin C in heart failure is nothing more than a bystander of glomerular filtration. J Nephrol. 2007;20:219-227.
34. Florvall G, Basu S, Larsson A. Apolipoprotein A1 is a stronger prognostic marker than are HDL and LDL cholesterol for cardiovascular disease and mortality in elderly men. Gerontol A Biol Sci Med Sci. 2006;61:262-266.
35. Hermann W, Quast S, Ellgass A, et al. An increased serum level of Apo(a) in renal patients is more restricting than Lp(a) in hemodialysis patients and is influenced by homocystein. Nephron. 2000;85:41-49.
36. Frischmann ME, Kronenberg F, Trenkwalder E, et al. In vivo turnover study demonstrates diminished clearance of Lp (a) in hemodialysis patients. Kidney Int. 2007;71:961-962.
37. Soriano S, González L, Martin-Malo A, et al. C-reactive protein and low albumin are predictors of morbidity and cardiovascular events in (CKD) 3-5 patients. Clin Nephrol. 2007;6:352-357.
38. Joki N, Hase H, Tanaka Y, et al. Relationship between serum albumin level before initiating hemodialysis and angiographic severity of coronary atherosclerosis in end-stage renal disease patients. Nephrol Dial Transplant. 2006;21:1633-1639.